세계의 테크네튬-99m 시장 보고서(2025년)
Technetium-99m Global Market Report 2025
상품코드 : 1811045
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 테크네튬-99m 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년까지 CAGR 4.9%로 확대되어 57억 4,000만 달러로 성장할 것으로 예상됩니다. 예측기간에 예측되는 성장은 핵의료 이미징 기능의 확대, 노인 증가, 진단량 증가, 암 이환율의 상승, 하이브리드 이미징 시스템의 채용 확대 등에 기인하고 있습니다. 이 기간의 주요 동향으로는 지속 가능한 동위 원소 기술 개발, 비 반응기 기반 제조 방법, 방사성 의약품 기술의 진보, 인공지능과의 통합, 방사성 의약품 제조 혁신 등이 있습니다.

영상 진단 절차에 대한 수요 증가가 향후 테크네튬-99m 시장의 성장을 이끌 것으로 예측됩니다. 영상 진단은 체내를 시각적으로 표현하는 의료 기술을 포함하며, 의사가 다양한 증상을 진단하거나 때로는 치료를 안내하는 데 도움이 됩니다. 이러한 수요 증가는 조기적이고 정확한 진단을 필요로 하는 만성질환의 만연으로 인한 것이 큽니다. 테크네튬-99m은 핵의료 스캔에서 상세한 영상를 생성하는 방사성 특성을 이용하여 의사가 장기와 조직의 기능을 높은 정밀도로 시각화할 수 있게 함으로써 영상 진단을 지원합니다. 예를 들어 영국 정부 기관인 NHS England에 따르면 2023년 3월기 영국의 영상 검사 건수는 4,500만 건으로 전년 4,400만 건에서 2.2% 증가했습니다. 이와 같이 영상 진단에 대한 수요 증가가 테크네튬-99m 시장의 성장을 뒷받침하고 있습니다.

테크네튬-99m 시장의 각 회사는 복잡한 병리에 대한 영상 진단의 정확성과 사용 편의성을 향상시키기 위해 첨단 방사성 의약품 이미징 약물과 같은 혁신적인 솔루션의 개발에 주력하고 있습니다. 이러한 약물은 방사성 물질로 표지된 특수 화합물이며 의사가 영상 기술을 사용하여 체내 구조를 시각화하는 데 도움이 됩니다. 예를 들어 2024년 6월 영국의 임상방사성의약품회사인 Serac Healthcare Limited는 16세 이상의 여성에게 표재성 복막 자궁내막증의 가시화와 진단을 위해서 설계된 혁신적인 SPECT-CT 이미징 약제인 99mTc-마라시클라티드에 대해 미국 FDA로부터 패스트 트랙 승인을 받았습니다. 본제는 자궁내막증 병변에서 과발현하고 있는 인테그린에 결합하는 테크네튬-99m 표지 표적 펩티드이며, SPECT-CT 검사에서 질환 부위를 명확하게 가시화할 수 있습니다. 이것은 복강경 수술을 대체하는 비침습적 진단 방법을 제공하며 자궁 내막증이 의심되는 여성에게 더 안전하고 사용하기 쉬운 진단 옵션을 설명합니다. 테크네튬-99m의 이상적인 반감기나 감마선 방출 에너지 등의 양호한 화상 특성을 이용함으로써, 본 약제는 방사선 피폭을 최소화하면서 고품질의 진단 화상을 기재하고 있습니다. 이 기술 혁신에 의해 자궁내막증 관리에서 진단 정밀도의 향상과 보다 좋은 치료 방침의 결정이 기대되는 것과 동시에, 테크네튬-99m을 이용한 화상 진단의 여성 의료에서 임상 응용의 폭이 넓어질 것으로 기대됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Technetium-99m (Tc-99m) is a radioactive isotope of technetium commonly used in nuclear medicine for diagnostic imaging. It emits gamma rays that can be detected by a gamma camera, enabling visualization of internal organs and structures. With a short half-life of approximately 6 hours, Tc-99m limits patient radiation exposure while delivering clear imaging results.

The primary products related to technetium-99m include radiopharmaceuticals, diagnostic kits, and generators. Radiopharmaceuticals are radioactive compounds used in medical imaging and therapy for diagnosis or treatment. These are available in various formulations such as liquid, solid, and freeze-dried forms. Applications span single photon emission computed tomography (SPECT), positron emission tomography (PET), oncology, cardiology, neurology, and more. The key end users include hospitals, diagnostic imaging centers, research laboratories, specialized clinics, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The technetium-99m market research report is one of a series of new reports from The Business Research Company that provides technetium-99m market statistics, including technetium-99m industry global market size, regional shares, competitors with a technetium-99m market share, technetium-99m market segments, market trends and opportunities, and any further data you may need to thrive in the technetium-99m industry. This technetium-99m market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The technetium-99m market size has grown strongly in recent years. It will grow from $4.52 billion in 2024 to $4.75 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historic period can be attributed to the expanding applications of nuclear medicine, rising demand for cancer and cardiac diagnostics, increased dependence on molybdenum-99 supply, growing demand for radiopharmaceuticals, and the heightened use of imaging in clinical trials.

The technetium-99m market size is expected to see steady growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth projected for the forecast period can be attributed to expanding nuclear imaging capabilities, an increasing geriatric population, a higher volume of diagnostics, rising cancer incidence, and growing adoption of hybrid imaging systems. Key trends during this period include the development of sustainable isotope technologies, non-reactor-based production methods, advancements in radiopharmaceutical technologies, integration with artificial intelligence, and innovations in radiopharmaceutical manufacturing.

The growing demand for diagnostic imaging procedures is expected to drive the growth of the technetium-99m market moving forward. Diagnostic imaging procedures involve medical techniques that create visual representations of the body's interior, assisting doctors in diagnosing and sometimes guiding treatment for various conditions. This rising demand is largely due to the increasing prevalence of chronic diseases that require early and accurate diagnosis. Technetium-99m supports diagnostic imaging by enabling doctors to visualize organ and tissue functions with high precision, using its radioactive properties to produce detailed images during nuclear medicine scans. For example, according to NHS England, a UK government department, 45.0 million imaging tests were performed in England in the year ending March 2023, reflecting a 2.2% increase compared to the 44.0 million tests conducted the previous year. Thus, the rising demand for diagnostic imaging is fueling the technetium-99m market's growth.

Companies in the technetium-99m market are focusing on developing innovative solutions such as advanced radiopharmaceutical imaging agents to improve the accuracy and accessibility of diagnostic imaging for complex medical conditions. These agents are special compounds labeled with radioactive materials that help doctors visualize internal body structures using imaging techniques. For instance, in June 2024, Serac Healthcare Limited, a UK-based clinical radiopharmaceutical company, received Fast Track Designation from the US FDA for 99mTc-maraciclatide, an innovative SPECT-CT imaging agent designed to visualize and diagnose superficial peritoneal endometriosis in women aged 16 and older. This agent is a technetium-99m-labeled targeted peptide that binds to integrins overexpressed in endometriosis lesions, allowing clear visualization of disease sites during SPECT-CT scans. It offers a non-invasive diagnostic alternative to laparoscopic procedures, providing a safer and more accessible diagnostic option for women suspected of having endometriosis. Utilizing the favorable imaging characteristics of technetium-99m, including its ideal half-life and gamma emission energy, this agent delivers high-quality diagnostic images while minimizing radiation exposure. This innovation is expected to improve diagnostic accuracy and support better treatment decisions in endometriosis management, while broadening the clinical use of technetium-99m-based imaging in women's health.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired ARTMS Inc. for an undisclosed sum. Through this acquisition, Telix aims to strengthen its control over the supply chain for key medical isotopes such as technetium-99m by integrating ARTMS's cyclotron-based radioisotope production technology. This move is intended to support large-scale, cost-effective, and reliable production of diagnostic and therapeutic isotopes within Telix's radiopharmaceutical portfolio. ARTMS Inc. is a Canada-based company specializing in advanced cyclotron technologies for producing medical radioisotopes including technetium-99m.

Major players in the technetium-99m market are Cardinal Health Inc., Siemens Healthineers AG, Philips Healthcare , GE Healthcare Technologies Inc. , BWX Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., China Isotope & Radiation Corporation (CIRC), Jubilant Pharma Limited, Curium Pharma LLC, Eckert & Ziegler Strahlen, Telix Pharmaceuticals Limited, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd., Advanced Cyclotron Systems Inc., Cyclopharm Limited, SHINE Technologies LLC, Medi-Radiopharma Kft., and SDS Lifesciences Pvt Ltd.

North America was the largest region in the technetium-99m market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in technetium-99m report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the technetium-99m market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The technetium-99m market includes revenues earned by entities by providing services such as diagnostic imaging, functional imaging, medical diagnostic imaging, cardiac imaging, and cancer detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The technetium-99m market also includes sales of technetium-99m sestamibi, mercaptoacetyltriglycine, hexamethylpropyleneamine oxime, technetium-99m pertechnetate, and diethylenetriamine pentaacetic acid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Technetium-99m Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on technetium-99m market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for technetium-99m ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The technetium-99m market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Technetium-99m Market Characteristics

3. Technetium-99m Market Trends And Strategies

4. Technetium-99m Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Technetium-99m Growth Analysis And Strategic Analysis Framework

6. Technetium-99m Market Segmentation

7. Technetium-99m Market Regional And Country Analysis

8. Asia-Pacific Technetium-99m Market

9. China Technetium-99m Market

10. India Technetium-99m Market

11. Japan Technetium-99m Market

12. Australia Technetium-99m Market

13. Indonesia Technetium-99m Market

14. South Korea Technetium-99m Market

15. Western Europe Technetium-99m Market

16. UK Technetium-99m Market

17. Germany Technetium-99m Market

18. France Technetium-99m Market

19. Italy Technetium-99m Market

20. Spain Technetium-99m Market

21. Eastern Europe Technetium-99m Market

22. Russia Technetium-99m Market

23. North America Technetium-99m Market

24. USA Technetium-99m Market

25. Canada Technetium-99m Market

26. South America Technetium-99m Market

27. Brazil Technetium-99m Market

28. Middle East Technetium-99m Market

29. Africa Technetium-99m Market

30. Technetium-99m Market Competitive Landscape And Company Profiles

31. Technetium-99m Market Other Major And Innovative Companies

32. Global Technetium-99m Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Technetium-99m Market

34. Recent Developments In The Technetium-99m Market

35. Technetium-99m Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기